Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials

A META-ANALYSIS OF BEMPEDOIC ACID FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS

(2020) Amanda Fernandes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mechanisms of statin-associated skeletal muscle-associated symptoms

(2019) Jamal Bouitbir et al.   PHARMACOLOGICAL RESEARCH

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

(2019) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mendelian Randomization Study of ACLY and Cardiovascular Disease

(2019) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials

(2019) Chengfeng Qiu et al.   Lipids in Health and Disease

Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials

(2019) Xiaolin Wang et al.   Kardiologia Polska

Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized, placebo-controlled trial

(2019) Narendra D. Lalwani et al.   Journal of Clinical Lipidology

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance

(2019) Ulrich Laufs et al.   Journal of the American Heart Association

Efficacy and Safety of Bempedoic Acid + Ezetimibe Fixed-Dose Combination in Patients at High CVD Risk and with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy

(2019) C. Ballantyne et al.   ATHEROSCLEROSIS

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease

(2019) Anne C. Goldberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

(2018) Christie M. Ballantyne et al.   ATHEROSCLEROSIS

Bempedoic Acid (ETC-1002)

(2018) Anum Saeed et al.   CARDIOLOGY CLINICS

Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology

(2018) José Tuñón et al.   CARDIOVASCULAR RESEARCH

Safety and efficacy of statin therapy

(2018) Bhavin B. Adhyaru et al.   Nature Reviews Cardiology

The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials

(2018) Reza Tabrizi et al.   PHARMACOLOGICAL RESEARCH

How to use Mendelian randomization to anticipate the results of randomized trials

(2017) Brian A Ference   EUROPEAN HEART JOURNAL

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Bempedoic Acid Reduces LDL-C and is Well-Tolerated in Patients Receiving Atorvastatin 80 mg Background Therapy

(2017) Mary McGowan et al.   Journal of Clinical Lipidology

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2017) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy

(2016) Christie M. Ballantyne et al.   AMERICAN JOURNAL OF CARDIOLOGY

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions

(2016) Michael G. Silverman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

(2016) Paul D. Thompson et al.   Journal of Clinical Lipidology

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

(2016) Stephen L. Pinkosky et al.   Nature Communications

Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance

(2015) Paul D. Thompson et al.   Journal of Clinical Lipidology

Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus

(2014) Maria J. Gutierrez et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients Across Four Phase 2a Studies

(2014) Roger S. Newton et al.   Journal of Clinical Lipidology

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

(2013) Christie M. Ballantyne et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY